Clinical Innovator Award
Clinical Innovator Award supports researchers conducting early-phase immunotherapy trials in chordoma, funding clinical research to translate promising therapeutic concepts into meaningful patient impact.
Browse similar grants
Funder: Chordoma Foundation
Due Dates: December 1, 2026 (Initial application)
Funding Amounts: Up to $1 million USD per clinical trial
Summary: Supports early-phase immunotherapy clinical trials in chordoma to translate promising concepts into patient impact.
Description
The Chordoma Foundation offers this award through its ongoing collaboration with the Cancer Research Institute (CRI) to accelerate innovative immunotherapy research in chordoma. Delivered through CRI’s Clinical Innovator program, the opportunity supports immunotherapy-focused clinical research, specifically early-phase clinical trials aimed at translating promising therapeutic concepts into meaningful impact for patients.
The award is part of the Foundation’s broader commitment to high-impact chordoma research addressing priorities defined by its medical and scientific advisors. Those priorities include target discovery, predictive biomarkers, mechanisms of immune evasion, and drug discovery focused on Brachyury, also known as TBXT. These broader research priorities provide context for the Foundation’s mission; this award focuses on clinical investigation of immunotherapy in chordoma.
